JPRN-jRCT2080220095未知Unknown
A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)
Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party0 个研究点开始时间: 2005年9月12日最近更新:
试验速览
- 阶段
- Unknown
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •[Inclusion criteria]
- •Patients with chronic obstructive pulmonary disease who are 40 years old or more, current smoker or ex-smoker, 30 to 80 % of predicted FEV1 after inhalation of short acting beta stimulant.
- •[Exclusion criteria]
- •Patients with poorly controlled COPD, patients who need for long-term oxygen therapy, patients who have concurrent respiratory diseases such as asthma, diffuse panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans, bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myaoma), which are considered to affect the evaluation.
排除标准
- 未提供
研究者
相似试验
未知
Unknown
A confirmatory study of APTA-2217 in adult patients with bronchial asthma (A placebo-controlled double-blind comparative study)Bronchial asthmaJPRN-jRCT2080220094Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ATTaiho Oncology, Inc.100
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-FRTaiho Oncology, Inc.100
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ESTaiho Oncology, Inc.100
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with Chronic Back PaiChronic back painCTIS2022-502151-54-00Cannaxan GmbH558